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Background: Defensins are antimicrobial peptides 
 expres sed on mucosal surfaces that contribute to maintaining 
intestinal homeostasis by providing innate defense mecha-
nisms for the epithelia. Defensin expression is altered in a num-
ber of diseases that affect mucosal surfaces, such as atopic 
dermatitis, allergic rhinitis, and inflammatory bowel disease. 
Similar to atopic dermatitis, eosinophilic esophagitis (EoE) is 
a chronic disease in which the squamous epithelial surface is 
affected by a similar T
H
2 microenvironment and eosinophil-
predominant inflammation. Therefore, we hypothesized that 
defensin expression would be decreased in EoE.
Methods: To address this, we measured defensin expression 
in vitro in cell lines derived from patients with EoE (EoE1-T) or gas-
troesophageal reflux disease (GERD) (NES-G4T cells) and ex vivo 
in esophageal mucosal biopsy samples from children with EoE 
or GERD and control children without esophageal disease.
results: Interleukin-5 induced a decrease in human 
β-defensin (hBD) -1 and hBD3 expression in EoE1-T but not in 
NES-G4T cells. Compared with esophageal biopsy specimens 
from GERD and control children, specimens from EoE pediatric 
patients revealed a significant decrease in mRNA and protein 
expression for hBD1 and hBD3.
conclusion: Diminished expression of hBD1 and hBD3 
may make the esophageal epithelium more susceptible to the 
development and/or perpetuation of EoE.
the esophageal epithelium is continuously bathed with dietary proteins, environmental allergens, and microbes. 
In this regard, the stratified squamous epithelium provides a 
physical barrier to the luminal microenvironment. Secreted 
bicarbonate, mucus, and antimicrobial peptides form integral 
parts of the innate esophageal mucosal defense mechanisms 
(1). Groups of these endogenous antimicrobials are termed 
defensins, a family of cationic proteins with broad activity 
against Gram-positive and Gram-negative bacteria, fungi, and 
enveloped viruses. The two major functions of defensins are to 
protect from pathogenic invasion of microbes and govern the 
commensal microbiota (2,3). Human β-defensin (hBD) -1 is 
constitutively expressed, whereas others are induced by infec-
tious or inflammatory stimuli (4–6).
An increasing body of data demonstrates that dysregulation 
or deficiencies in epithelial defensin expression may predis-
pose the mucosal surface to microbial invasion and disease 
exacerbation. For instance, patients with atopic dermatitis, a 
chronic disease characterized by infiltration of the dermis with 
eosinophils, have deficiencies in hBD2, hBD3, and cathelicidin 
(LL-37), as well as single-nucleotide polymorphisms in hBD1 
(7–14).
Eosinophilic esophagitis (EoE) is a chronic inflammatory 
disease of the esophagus mediated by an immune/allergen 
response leading to eosinophil accumulation in the esopha-
geal mucosa. Symptoms frequently mimic those of gastro-
esophageal reflux disease (GERD), but the diseases appear to 
be distinct in their gene expression, response to therapy, and 
association with allergies (15,16). To date, pathogenic mecha-
nisms are not certain, but genetic perturbations in eotaxin-3, 
thymic stromal lymphopoietin, and filaggrin have been identi-
fied and may contribute (17). Because EoE has been consid-
ered an atopic disease, similar to atopic dermatitis because of 
its predilection to the squamous epithelia, atopic etiology, and 
eosinophilic nature, we hypothesized that defensin expression 
was diminished in the epithelia affected by EoE, and this may 
contribute to the initiation and/or perpetuation of esophageal 
inflammation.
RESULTS
Expression of hBD Is Decreased in Human EoE Cells
To determine whether there was a rationale for addressing our 
hypothesis, we first examined whether esophageal epithelial 
cells express defensins in vitro using previously described cell 
lines derived from adults with EoE (EoE1-T) or GERD (NES-
G4T) (18,19). Both cell lines expressed hBD1, hBD2, and hBD3 
mRNA at baseline. Unstimulated confluent monolayer cultures 
of EoE1-T cells demonstrated significantly lower expression of 
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hBD1 and hBD3 compared with NES-G4T cells (60% decrease 
in hBD1, P < 0.001; 40% decrease in hBD3, P < 0.01; EoE1-T 
compared with NES-G4T). There was no significant change in 
the expression of hBD2 in EoE1-T compared with NES-G4T 
cells (Figure 1).
To simulate an EoE microenvironment, EoE1-T and NES-
G4T cells were incubated with interleukin (IL)-5, an impor-
tant eosinophil growth factor elevated in mucosal biopsies of 
patients with EoE (20), and the expression of hBD1 and hBD3 
was measured. Stimulation of cells with IL-5 led to a decrease 
in defensin mRNA expression of hBD1 and hBD3 in EoE1-T 
but not NES-G4T cell lines (Figure 2).
Expression levels of other antimicrobial peptides includ-
ing LL-37, hBD2, hBD4, and hBD5 were not shown to differ 
either at baseline or following stimulation comparing EoE1-T 
and NES-G4T cell lines and thus were not examined further. 
Because our in vitro findings identified changes in only hBD1 
and hBD3, we only examined expression of these defensins in 
esophageal biopsy studies as reported below.
Defensin Expression Is Decreased in Esophageal Mucosa From 
EoE Subjects
We next measured defensin expression in human esophageal 
biopsies obtained from well-characterized pediatric subjects 
(Table 1). Included in the study were 11 control subjects with-
out esophageal disease (mean age: 11.7 ± 4.5 y, 55% male, 90% 
Caucasian), 9 GERD subjects (mean age: 11.9 ± 6.4 y, 60% male, 
80% Caucasian, 60% on proton pump inhibitor therapy), 9 sub-
jects with untreated EoE (mean age: 10.1 ± 6.1 y, 55% male, 88% 
Caucasian), and 13 subjects with EoE who had received treatment 
(mean age: 9.0 ± 3.5 y, 46% male, 92% Caucasian). Four of the 13 
EoE-treated subjects continued to have active inflammation.
Figure 1. mRNA expression of human β-defensins in human esophageal squamous epithelial cells. Quantitative real-time PCR was performed using RNA iso-
lated from NES-G4T (GERD cells) and EoE1-T (EoE cells). (a) Human β-defensin 1, ‡P < 0.001. (b) Human β-defensin 2. (c) Human β-defensin 3, **P < 0.01. Relative 
expression compared with 18S. Results are representative of four separate experiments. EoE, eosinophilic esophagitis; GERD, gastroesophageal reflux disease.
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Figure 2. In vitro culture experiment of human esophageal squamous epithelial cells, EoE1-T, and NES-G4T with increasing concentrations of IL-5 (ng/ml). 
(a) EoE1-T-hBD1, (b) EoE1-T-hBD3, (c) NES-G4T-hBD1, and (d) NES-G4T-hBD3. Changes in mRNA expression are shown relative to baseline expression in 
each cell line. *P < 0.05; **P < 0.01; ‡P < 0.001; NS, not significant. Relative expression compared with 18S. Results are representative of three separate 
experiments. EoE, eosinophilic esophagitis; hBD, human β-defensin; IL, interleukin.
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Expression of hBD1 and hBD3 was significantly reduced in 
subjects with EoE compared with healthy controls (hBD1-EoE 
vs. normal: P < 0.0001; hBD3-EoE vs. normal: P < 0.001). No 
significant differences were measured in defensin expression in 
GERD subjects compared with healthy controls (hBD1-GERD 
vs. normal: P = 0.9; hBD3-GERD vs. normal: P = 0.7) regard-
less of proton pump inhibitor treatment. GERD subjects had 
defensin expression levels similar to those of normal subjects 
and did not have decreased expression as seen in EoE.
To determine the impact of treatment on defensin expres-
sion, we next compared hBD1 and hBD3 mRNA levels in 
mucosal biopsies from subjects with active, untreated EoE 
with those who had undergone treatment. hBD1 and hBD3 
expression in active as well as treated EoE was significantly 
decreased compared with normal control mucosa (Figure 3). 
When controlling for inflammation, on the basis of eosinophil 
numbers in the esophageal mucosa, there was a trend toward 
restitution of hBD1 and hBD3 levels in message expression, 
but this did not reach statistical significance.
Immunohistochemical Analysis of hBD Protein
To determine whether defensin protein patterns were consistent 
with the above mRNA expression levels, we performed immu-
nohistochemistry analysis of hBD1 and hBD3 from the same 
subject samples. Normal subject samples revealed diffuse hBD1 
and hBD3 staining of the epithelia with predominance along the 
luminal border. In contrast, samples from active and treated EoE 
revealed minimal or no epithelial staining (Figure 4).
To provide a semiquantitative analysis of defensin staining, 
we used a computer-generated scoring system. Our results 
demonstrated significantly decreased hBD1 and hBD3 mean 
intensity scores in active and treated EoE samples compared 
with normal control mucosa (hBD1: 12.5 vs. 16.6, P < 0.05, 
EoE active vs. normal; 10.1 vs. 16.6, P < 0.01, EoE treated vs. 
 normal and hBD3: 12.3 vs. 16.4, P < 0.05, EoE active vs. normal; 
table 1. Description of 38 patients in four experimental groups
Diagnosis
Eosinophils 
per HPF Age (y) Atopy Treatment
EoE
 1 >100 4 Y None
 2 >100 4 Y None
 3 90 5 Y None
 4 30 12 Y None
 5 25 19 N None
 6 20 19 N None
 7 19 12 Y None
 8 15 11 Y None
 9 15 5 N None
Treated EoE
 1 64 12 Y Topical 
glucocorticoid
 2 25 4 Y Topical 
glucocorticoid/
diet/PPI
 3 23 7 N Topical 
glucocorticoid
 4 22 13 N Topical 
glucocorticoid/diet
 5 15 8 Y Topical 
glucocorticoid/
diet/PPI
 6 10 8 Y Diet
 7 5 8 Y Topical 
glucocorticoid/diet
 8 3 8 Y Topical 
glucocorticoid/diet
 9 2 18 Y Topical 
glucocorticoid
 10 1 7 N Topical 
glucocorticoid/diet
 11 1 8 Y Topical 
glucocorticoid/diet
 12 0 7 Y Topical 
glucocorticoid/PPI
 13 0 9 Y Topical 
glucocorticoid
Control
 1 0 10 N None
 2 0 8 N None
 3 0 11 N None
 4 0 19 Y None
 5 0 3 Y None
 6 0 15 N None
 7 0 8 N None
 8 0 13 Y None
 9 0 11 Y None
 10 0 15 N None
 11 0 16 N None
table 1. Continued
Diagnosis
Eosinophils 
per HPF Age (y) Atopy Treatment
GERD
 1 10 17 Y PPI
 2 7 19 N None
 3 5 22 Y PPI
 4 5 7 Y None
 5 2 15 Y PPI
 6 0 5 N None
 7 0 8 Y None
 8 0 5 Y None
 9 0 6 N PPI
Description of 38 patients (42 biopsies) in four experimental groups: control, 
eosinophilic esophagitis (EoE), EoE treated, and gastroesophageal reflux disease 
(GERD). Esophageal histology including eosinophil number and reactive changes 
(basal zone hyperplasia, rete peg elongation, or spongiosis) were determined by a staff 
pathologist. Topical glucocorticoids include fluticasone, budesonide, and ciclesonide.
HPF, high-power field; N, no; PPI, proton pump inhibitor; Y, yes.
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11.6 vs. 16.4, P < 0.01, EoE treated vs. normal). Figure 4c and d 
illustrates the sum intensity for each group.
Examination of the defensin staining pattern indicated 
that the predominant staining in normal epithelia occurred 
within the superficial epithelial cells. To determine whether 
the hyperplastic basal cells were associated with less hBD1 
and hBD3 protein expression, we correlated defensin staining 
with basal cell hyperplasia in all subjects’ tissues. The degree 
of basilar cell hyperplasia inversely correlated with the degree 
of defensin staining, suggesting that the decreased hBD1 and 
hBD3 expression observed in EoE may be related to the loss 
of the superficial epithelia rather than decreased epithelial 
expression of these molecules (Figure 5).
DISCUSSION
EoE is a chronic esophageal disease of undetermined etiology 
that bears many similarities to atopic dermatitis. Because a num-
ber of lines of evidence suggest that the epithelial barrier may 
be defective in atopic dermatitis and EoE, we hypothesized that 
defensins, one form of esophageal innate immunity, would be 
decreased in EoE, similar to the epithelia in atopic dermatitis. 
Our novel findings demonstrate that hBD1 and hBD3 expression 
Figure 3. mRNA expression of (a) hBD1and (b) hBD3 in control (n = 11), EoE (n = 9), and EoE-treated (n = 13) human esophageal biopsies, ‡P < 0.001;  
NS, not significant. EoE, eosinophilic esophagitis; hBD, human β-defensin.
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Figure 4. Immunohistochemical staining for (a) hBD1 and (b) hBD3 in esophageal mucosal biopsies from healthy controls compared with EoE and 
EoE-treated subjects. Magnification is ×20 and scale bar represents 100 μm in all images. Staining intensity of the luminal epithelial surface from biopsy 
samples of healthy controls, EoE, and EoE-treated subjects for (c) hBD1 and (d) hBD3. Intensity staining was measured by microscopy; the graph  
represents the sum intensity score for each group. *P < 0.05; **P < 0.01. EoE, eosinophilic esophagitis.
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is decreased in the esophageal epithelia affected by EoE com-
pared with that from normal and GERD esophageal tissues.
To support a rationale for our studies, we first used immor-
talized, nonneoplastic esophageal cell lines derived from 
patients with EoE and GERD and identified decreased expres-
sion of hBD1 and hBD3 in EoE compared with GERD cells. In 
addition, IL-5, a cytokine that plays a key role in the pathogen-
esis of EoE (18,21), induced the downregulation of hBD1 and 
hBD3 in EoE but not in GERD cells, suggesting that EoE cells 
possess different phenotypic alterations than GERD cells. The 
choice of IL-5 as an agonist was based on the previous findings 
that demonstrate increased esophageal expression of IL-5 in 
tissues of patients affected by EoE, increased circulating levels 
of IL-5 from peripheral eosinophils from patients with EoE, 
the IL-5 dependency of esophageal eosinophilia in murine 
models, and the histological impact of anti-IL-5 on reducing 
eosinophils in therapeutic EoE trials (18–23). Future studies 
will determine whether other EoE-related cytokines, including 
IL-13, also alter esophageal defensin expression.
To determine the biological relevance of these findings, we 
next measured defensin expression in mucosal biopsies from 
well-defined subjects with active EoE, treated EoE, GERD, and 
normal esophagus. Although defensin expression did not dif-
fer between normal and GERD tissues, significant reductions 
in both hBD1 and hBD3 expressions were measured in EoE 
tissues as compared with the expression in normal tissues. This 
influence did not seem to depend on the presence or absence 
of eosinophils because defensin expression was reduced both 
in treated tissues that showed histological remission and in tis-
sues that contained eosinophils. Together, these results show 
that the esophageal squamous epithelium from patients with 
EoE express less hBD1 and hBD3 than controls and suggest 
that this expression pattern may predispose the patients with 
EoE to barrier dysfunction.
One intriguing observation is that the pattern of immuno-
histochemical staining for hBD1 and hBD3 differs in normal 
compared with inflamed and treated tissues. Normal tissues 
demonstrated prominent staining throughout the epithe-
lium with predominance at the luminal surface. In contrast, 
the inflamed tissue showed a diminished staining pattern 
throughout the epithelium. One possible interpretation of the 
reduced expression pattern in inflammation is that the major-
ity of defensin expression is contained within the mature cells 
at the luminal surface and not in the regenerating basal cells 
that predominate in active EoE. This is supported by the corre-
lation of the hBD1 and hBD3 staining intensity with basal zone 
hyperplasia score. To date, little is known regarding the specific 
phenotypes and features of each layer of the stratified esopha-
geal epithelium, but a robust literature supports phenotypic 
differences within the stratified squamous epithelium of the 
skin, raising the possibility that this also exists in the esopha-
geal mucosa (24). Future studies that dissect specific cell popu-
lations within the esophageal epithelium will better determine 
the mechanisms for this differential expression pattern.
Defensins are a family of variably cationic 3- to 5-kDa pep-
tides with a conserved motif of six disulfide-linked cysteines. 
They display a broad spectrum of antimicrobial activity through 
micropore formation in the phospholipid bilayer of bacterial 
membranes (25,26). The production of hBD1 is constitutive, but 
other defensins are induced by infectious or inflammatory stim-
uli (2,4,5), and little is known about esophageal defensins (27,28). 
Atopic dermatitis is a chronic inflammatory disease affecting the 
squamous epithelium of the skin that is characterized by over-
expression of TH2 cytokines and epithelial eosinophilia, as well 
as by a propensity for staphylococcal and herpetic infections. 
Multiple studies have shown that the increased predisposition 
to skin infections is caused by decreases in epithelial barrier 
function (mechanical skin breakdown and abnormal expres-
sion of filaggrin) and by dysregulation in dermally expressed 
defensins (9–12,29–31). Although the microbiome of EoE is not 
currently characterized, certain immunological features of these 
two diseases are quite similar, and thus we wondered whether 
there may be similarities with respect to defensin expression. For 
instance, in atopic dermatitis, hBD2, hBD3, and LL-37 expres-
sion is decreased in skin lesions, and at least one single nucleo-
tide polymorphism in hBD1 has been described (6–14,29–33). 
In addition, dysregulation of defensins may contribute to the 
initiation or perpetuation of gastrointestinal diseases. Paneth cell 
and epithelial defensin expression is diminished in Crohn’s and 
celiac diseases (3,4,26,34–37). Whether these changes in defen-
sin expression reflect decreased epithelial barrier function from 
underlying inflammation, changes in the luminal microbiome, 
or gene variations and polymorphisms remains uncertain.
Figure 5. Log-transformed basal epithelial defensin protein expression to 
degree of basal zone cell hyperplasia for hBD1 and hBD3 in control and all 
EoE subjects. Spearman correlation for (a) hBD1, r = 0.626, ‡P < 0.001, and 
(b) hBD3, r = 0.712, ‡P < 0.001. EoE, eosinophilic esophagitis; hBD, human 
β-defensin.
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Decreased defensin expression in EoE could be explained 
by the overexpression of the TH2 cytokine, IL-5. In a murine 
model of EoE, inflammation and remodeling are dependent on 
the presence of IL-5, and human studies have shown that not 
only increased levels of this cytokine in patients with EoE, but 
also therapeutic targeting of IL-5 results in diminished esopha-
geal eosinophilia (18,19,22,23). Our in vitro findings show that 
IL-5 decreases defensin expression in the EoE cell line, sup-
porting a potential role for IL-5 in decreasing the functional 
esophageal barrier. IL-5 did not decrease defensin expression 
in the GERD cell line, suggesting that regulation of defensin 
expression may differ between the two diseases.
One limitation of our study is that some subjects were treated 
for EoE or GERD at the time of their esophageal biopsies, and 
the impact of those treatments on our study results are not 
known. In the limited number of samples studied, however, 
no differences were noted in defensin expression based on the 
treatment received.
We have demonstrated that esophageal defensin expression 
is decreased in EoE. We speculate that these alterations in 
innate defense molecules might be a novel pathogenic mecha-
nism for the development of EoE. Alterations in esophageal 
defensins were specific for EoE when compared with healthy 
controls and GERD. If confirmed in larger studies, defensin 
expression may serve as another biomarker helping to dis-
tinguish GERD from EoE. Future studies that define regula-
tory mechanisms for esophageal defensins will be critical to 
increasing our understanding about the role of defensins in 
esophagitis and the therapeutic utility of esophageal defensins 
as a part of the therapeutic armamentarium for EoE.
METHODS
Cell Culture and Reagents
Telomerase-immortalized human esophageal epithelial cells were 
isolated from patients with GERD (NES-G4T) and EoE (EoE1-T) 
as described previously (38). NES-G4T and EoE1-T (300,000 per 
well) (passages 87–97 and 86–94, respectively) were grown in 6-well 
plates (BD Biosciences, San Jose, CA) at 37 °C in a humidified 5% 
CO2 incubator in supplemented keratinocyte basal medium, KBM-2 
(Cambrex, East Rutherford, NJ). The cells were incubated with the 
cytokine IL-5 (R&D Systems, Minneapolis, MN) at varying concen-
trations and RNA was isolated.
RNA Extraction and Real-Time Quantitative PCR for Esophageal 
Epithelial Cells
Cells were lysed with β-mercaptoethanol containing RLT cell lysis buf-
fer (10 μl β-mercaptoethanol per 1 ml RLT buffer) for 5 min and RNA 
was harvested using a Qia-shredder and RNeasy kit (Qiagen, Valencia, 
CA) per the manufacturer’s recommendations. Isolated RNA was mea-
sured using nanotechnology (Nanodrop; Thermo Fisher Scientific, 
Wilmington, DE) and equalized to 0.5 μg per sample. Samples were 
reverse transcribed using a high-capacity cDNA reverse transcriptase 
kit (Applied Biosystems, Foster City, CA). Preformulated TaqMan 
gene expression assays (Applied Biosystems) were utilized to quan-
tify the expression of hBD genes: DEFB1 (Hs00608345_m1) DEFB4 
(Hs00823638_m1), DEFB103 (Hs04194486_g1), and 18S (Hs99999901_
s1). Quantitative real-time PCR was performed (AbsoluteBlue 
Mastermix, Fisher Scientific, Pittsburgh, PA) using 96-well optical 
plates (Applied Biosystems) on the 7300 RT-PCR platform (Applied 
Biosystems). All samples were normalized to 18S using the ∆∆CT 
method of relative quantitation, where CT was the threshold cycle.
Human Esophageal Tissue Analyses
Pediatric subjects cared for at the Digestive Health Institute at the 
Children’s Hospital Colorado who underwent endoscopy and muco-
sal biopsy were recruited for this study. This study was approved by 
the Colorado Multiple Institutional Review Board. Written informed 
consent and Health Insurance Portability and Accountability Act 
authorization were obtained from all participants or from parents or 
legal guardians of participants aged younger than 18 y. Assent was 
obtained from all participants aged younger than 18 y. Indications 
for procedures included symptoms of dysphagia, reflux, abdominal 
pain, vomiting, failure to thrive, and evaluation for EoE. Diagnostic 
criteria used to separate the subjects were as follows: (i) EoE active—
patients had symptoms related to esophageal dysfunction, eosinophil 
counts ≥15 eosinophils per high-power field (×40 magnification), 
and other diseases ruled out; these subjects were not on systemic or 
topical glucocorticoids, proton pump inhibitors, or dietary elimina-
tion at the time of their procedures; (ii) treated EoE—patients had 
EoE diagnosis previously, and treatments included topical steroids, 
proton pump inhibitors, and/or dietary elimination(s). The majority 
of these patients were asymptomatic, but all had repeated endoscopy 
to evaluate for histologic remission of esophageal eosinophilia; (iii) 
GERD—patients had symptoms related to esophageal dysfunction 
and <15 eosinophils per high-power field in either the distal or the 
proximal biopsy specimens and/or abnormal pH impedance studies; 
(iv) control subjects—patients had symptoms necessitating an endos-
copy, were not taking medications, and had normal esophageal biop-
sies. Subject characteristics are listed in Table 1. One set of esopha-
geal biopsies was placed in 10% buffered formalin for histopathologic 
analysis. Another set of esophageal biopsies was snap-frozen and 
stored at −80 °C for batch analysis as described below.
RNA Extraction and Real-Time Quantitative PCR of Human Tissues
Biopsy specimens were homogenized (Fisher Scientific) and RNA was 
isolated using an RNeasy kit (Qiagen) according to the manufactur-
er’s recommendations. RNA was equalized to 0.05 μg per sample. The 
same isolation and analytical methods used for in vitro studies above 
were used for human tissues.
Immunohistochemistry of Human Esophageal Tissues
Formalin-fixed paraffin-embedded samples were used for these stud-
ies. Patients undergoing endoscopy had one biopsy collected for RNA 
analysis and another clinical biopsy for histology. Five-micrometer 
sections were subjected to immunohistochemical staining as pre-
viously described (39,40) for hBD1 and hBD3. Briefly, slides were 
baked and rehydrated in serial xylene and ethanol concentrations, 
equilibrated in 1× phosphate-buffered saline, quenched with 3% 
H2O2 for 20 min, and blocked with 20% normal goat serum for 1 h at 
room temperature. Primary antibodies for hBD1 and hBD3 (Phoenix 
Pharmaceuticals, Burlingame, CA) were used at a concentration of 
1:500 diluted in phosphate-buffered saline and incubated overnight at 
4 °C. Slides were washed with 1× phosphate-buffered saline, blocked 
with avidin/biotin (Vector, Burlingame, CA), incubated with second-
ary biotinylated antibody (VECTASTAIN Elite ABC system; Vector) 
for 1 h at room temperature, and developed with permanent red 
(Dako North America, Carpinteria, CA).
Protein Analysis
Slides were coded and remained blind through the analysis. hBD1 and 
hBD3 immunostaining intensity was graded according to the follow-
ing protocol. A standardized region of interest was predetermined as 
3,000 μm2. This region of interest sample size was selected to control 
for bias and allowed for repetitive samplings from a single specimen 
to result in data with low variance. For each section (×20 high-power 
field), a region of interest containing contiguous staining, including 
both luminal and basal epithelia, was selected. Intensity was captured 
from a 3,000 μm2 area from both the basal and the luminal sides of 
the section, calculated relative to the area, and recorded using the ref-
erenced imaging software (Nikon; Nikon Instruments, Melville, NY). 
Separate intensity scores were assigned for luminal and basal epithelia 
using the standardized region of interest for each site. Sum luminal 
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intensity scores were then compared between different experimental 
groups (Figure 4).
Basal intensity scores were correlated to the degree of basal zone 
hyperplasia. Basal zone hyperplasia was scored as 1, 2, or 3, where 1 
= normal basal epithelium (2–4 cell layers thick), 2 = moderate basal 
epithelial hyperplasia (up to half of the biopsy being basal epithelium), 
and 3 = severe basal epithelial cell hyperplasia (up to three-fourths to 
full-thickness changes). Each tissue section was scored independently 
by three investigators (S.S., S.F., and R.H.) for the degree of basal zone 
hyperplasia.
Statistical Analysis
SAS1 9.2 and Prism (SAS Institute, Cary, NC) were used for statistical 
analysis. Defensin expression from cell culture experiments was com-
pared by two-sample t-test. Human defensins were compared across 
groups using one-way ANOVA and are represented as standard error 
in the figures. Protein from luminal and basal epithelium staining was 
not normally distributed; logarithmic transformation to the natural 
base was applied to the data. Luminal intensity graphs are presented 
in original scale, however. Spearman’s correlation coefficient (r) was 
used to assess the correlations between defensin protein and basal 
epithelial hyperplasia.
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